Aneurysmal Subarachnoid Hemorrhage Drugs Market is growing at a CAGR of 3.6% by 2023
Global aneurysmal subarachnoid hemorrhage drugs market was valued at $160,269 thousand in 2016, and is estimated to reach $206,675 thousand by 2023, growing at a CAGR of 3.6% from 2017 to 2023.Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4602
Aneurysmal subarachnoid hemorrhage is a kind of stroke, which is caused by bleeding in the subarachnoid space of the brain. The major reasons for aneurysmal subarachnoid hemorrhage include brain aneurysm, arteriovenous malformation, or head injury. Change in lifestyles such as smoking and alcohol consumption increase the risk for aSAH, as well as rise in geriatric population are the major factors that contribute to the growth of the market.
Moreover, increase in prevalence of hypertension, and stroke further boost the market growth. However, the associated side effects of the drugs are expected to impede the market growth. In addition, a need to create awareness about the optimal diagnosis and treatment of aneurysmal subarachnoid hemorrhage provide lucrative opportunities for the market growth.
Opioid analgesics generated the maximum revenue, accounting for more than two-fifths share of the global aneurysmal subarachnoid hemorrhage drugs market in 2016. The calcium channel blockers segment is expected to witness the highest CAGR of 4.5% during the forecast period, owing to their ability to reduce the risk of brain damage.
Key Findings of the Aneurysmal Subarachnoid Hemorrhage Drugs Market:
o The opioid analgesics segment is expected to grow at a significant CAGR of 2.6% during the forecast period.
o The anticonvulsants segment contributed nearly one-fourth share of the global aneurysmal subarachnoid hemorrhage drugs market in 2016.
o The stool softeners segment is projected to grow at a significant CAGR of 4.2% during the forecast period.
o Germany and France are the major shareholders, which collectively accounted for more than one-third share of the European aneurysmal subarachnoid hemorrhage drugs market in 2016.
o Japan is the major shareholder, accounting for more than one-third share of the Asia-Pacific aneurysmal subarachnoid hemorrhage drugs market in 2016.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4602
The Asia-Pacific market is projected to grow at the highest CAGR of 5.5% during the forecast period, owing to rise in awareness about the treatment of aneurysmal subarachnoid hemorrhage in the healthcare industry and surge in expenditures in emerging markets (such as India and China) to cater to the unmet medical needs.
The major companies profiled in the report are Arbor Pharmaceuticals Inc., Edge Therapeutics, Inc., Johnson & Johnson (Actelion Pharmaceuticals Ltd.), Mylan N.V., Orexo AB, Pfizer Inc., Purdue Pharma L.P., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.)
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com
Follow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aneurysmal Subarachnoid Hemorrhage Drugs Market is growing at a CAGR of 3.6% by 2023 here
News-ID: 2040812 • Views: โฆ
More Releases from Allied Market Research
Community Based Tourism Market Expected to Surge to $2136.8 Billion by 2032, Dri โฆ
According to a new report published by Allied Market Research, titled, "Community Based Tourism Market Size, Share, Competitive Landscape and Trend Analysis Report by Age, by Traveler Type, by Sales Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032." The report offers an in-depth examination of key investment areas, successful strategies, drivers, opportunities, market size estimations, competitive landscape, and evolving market trends. ๐๐ก๐ ๐๐จ๐ฆ๐ฆ๐ฎ๐ง๐ข๐ญ๐ฒ ๐๐๐ฌ๐๐ ๐ญ๐จ๐ฎ๐ซ๐ข๐ฌ๐ฆ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฐ๐๐ฌ ๐ฏ๐๐ฅ๐ฎ๐๐ ๐๐ญโฆ
K-pop Events Market Expected to Surge to $20 Billion by 2031, Driven by 7.3% CAG โฆ
According to a new report published by Allied Market Research, titled, "K-pop Events Market by Type (Rock, Jazz, Pop, Others), by Revenue Source (Tickets, Sponserships, Others), by Gender (Male, Female): Global Opportunity Analysis and Industry Forecast, 2021-2031". The report offers an extensive analysis of changing market trends, key segments, top investment pockets, regional scenario, Porter's Five Forces, and competitive scenario. ๐๐ก๐ ๐ค-๐ฉ๐จ๐ฉ ๐๐ฏ๐๐ง๐ญ๐ฌ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฐ๐๐ฌ ๐ฏ๐๐ฅ๐ฎ๐๐ ๐๐ญ $๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ข๐งโฆ
Music Event Market Size Value US$ 481.4 Billion by 2031, with a CAGR of 9.7% Rec โฆ
๐๐ก๐ ๐ฆ๐ฎ๐ฌ๐ข๐ ๐๐ฏ๐๐ง๐ญ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฐ๐๐ฌ ๐ฏ๐๐ฅ๐ฎ๐๐ ๐๐ญ $๐๐๐.๐๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ข๐ง ๐๐๐๐ ๐๐ง๐ ๐ข๐ฌ ๐๐ฌ๐ญ๐ข๐ฆ๐๐ญ๐๐ ๐ญ๐จ ๐ซ๐๐๐๐ก $๐๐๐.๐ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐ฒ ๐๐๐๐, ๐ ๐ซ๐จ๐ฐ๐ข๐ง๐ ๐๐ญ ๐ ๐๐๐๐ ๐จ๐ ๐.๐% ๐๐ซ๐จ๐ฆ ๐๐๐๐ ๐ญ๐จ ๐๐๐๐.
According to a new report published by Allied Market Research, titled "Music Event Market By Revenue Source, By Genre, By Type, By Age Group, By Gender: Global Opportunity Analysis and Industry Forecast, 2021-2031" The report provides a detailed analysis of theโฆ
Glamping Market Projected to Worth US$ 7.11 Billion by 2031, Growth Rate (CAGR) โฆ
According to a new report published by Allied Market Research, titled, "Glamping Market By Application, By Age Group, By Size, By End User, By Distribution Channel, By Product Type: Global Opportunity Analysis and Industry Forecast, 2021-2031". The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends. ๐๐ก๐ ๐ ๐ฅ๐๐ฆ๐ฉ๐ข๐ง๐ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฐ๐๐ฌ ๐ฏ๐๐ฅ๐ฎ๐๐ ๐๐ญ $๐.๐๐โฆ
More Releases for Aneurysmal
Aneurysmal Subarachnoid Hemorrhage Drugs Market Size & Growth Analysis Report, 2 โฆ
The global aneurysmal subarachnoid hemorrhage drugs market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Aneurysmal subarachnoid hemorrhage (aSAH) is a life-threatening type of stroke. It is caused by bleeding in the space surrounding the brain. It mostly occurs due to bursts and leaks of a weak area in a blood vessel on the surface of the brain due to which blood builds up aroundโฆ
Aneurysmal Subarachnoid Hemorrhage Market Real Time Analysis & Forecast 2017 โ โฆ
Global Aneurysmal Subarachnoid Hemorrhage Market : Snapshot
According to the National Institutes of Health (NIH), aneurysmal subarachnoid hemorrhage (SAH) has turned into a glaring health burden across the world and possesses high rates of permanent disabilities and fatalities. It has been estimated by the NIH that approximately 9 out of 100,000 people across the world suffer from some variation of aneurysmal subarachnoid hemorrhage, a number which is more concerning in theโฆ
Aneurysmal Subarachnoid Hemorrhage Market Prospective Growth 2025 - Arbor Pharma โฆ
Global Aneurysmal Subarachnoid Hemorrhage Market : Snapshot
According to the National Institutes of Health (NIH), aneurysmal subarachnoid hemorrhage (SAH) has turned into a glaring health burden across the world and possesses high rates of permanent disabilities and fatalities. It has been estimated by the NIH that approximately 9 out of 100,000 people across the world suffer from some variation of aneurysmal subarachnoid hemorrhage, a number which is more concerning in theโฆ
Aneurysmal Subarachnoid Hemorrhage Market Preventing challenges complications 20 โฆ
Global Aneurysmal Subarachnoid Hemorrhage Market : Snapshot
According to the National Institutes of Health (NIH), aneurysmal subarachnoid hemorrhage (SAH) has turned into a glaring health burden across the world and possesses high rates of permanent disabilities and fatalities. It has been estimated by the NIH that approximately 9 out of 100,000 people across the world suffer from some variation of aneurysmal subarachnoid hemorrhage, a number which is more concerning in theโฆ
Top Factors Driving the Global Aneurysmal Subarachnoid Hemorrhage Drugs Market
HTF MI recently introduced Global Aneurysmal Subarachnoid Hemorrhage Drugs Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. At present, the market is developing its presence and some of the key players from the complete study are Arbor Pharmaceuticals Inc. (US), Edge Therapeutics, Inc. (US), Johnson & Johnson (Actelion Pharmaceuticals Ltd.) (US), Mylan N.V. (US), Orexo AB (Sweden), Pfizerโฆ
Aneurysmal Subarachnoid Hemorrhage Market witness lethargic growth 2025
Global Aneurysmal Subarachnoid Hemorrhage Market : Snapshot
According to the National Institutes of Health (NIH), aneurysmal subarachnoid hemorrhage (SAH) has turned into a glaring health burden across the world and possesses high rates of permanent disabilities and fatalities. It has been estimated by the NIH that approximately 9 out of 100,000 people across the world suffer from some variation of aneurysmal subarachnoid hemorrhage, a number which is more concerning in theโฆ